Inauen 1991.

Methods	Number and location of sites not reported. Cross‐over trial with 3 treatment cycles on each oral contraceptive. Blinding not described.
Participants	Healthy women aged 18 to 30 years without oral contraceptive use during prior four months. Excluded blood coagulation disorders.
Interventions	EE 20 µg and desogestrel 150 µg (N=20) versus EE 50 µg and desogestrel 125 µg (N=20).
Outcomes	Blood coagulation, thrombogenesis, and side effects. Bleeding terms were not defined.
Notes	Randomization method not reported. 100% completed study.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Not reported